Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Selinexor synergizes with dexamethasone to repress mTORC1 signaling and induce multiple myeloma cell death.

Argueta C, Kashyap T, Klebanov B, Unger TJ, Guo C, Harrington S, Baloglu E, Lee M, Senapedis W, Shacham S, Landesman Y.

Oncotarget. 2018 May 22;9(39):25529-25544. doi: 10.18632/oncotarget.25368. eCollection 2018 May 22.

2.

Glycogen synthase kinase-3β mediated regulation of matrix metalloproteinase-9 and its involvement in oral squamous cell carcinoma progression and invasion.

Pramanik KK, Nagini S, Singh AK, Mishra P, Kashyap T, Nath N, Alam M, Rana A, Mishra R.

Cell Oncol (Dordr). 2018 Feb;41(1):47-60. doi: 10.1007/s13402-017-0358-0. Epub 2017 Nov 13.

PMID:
29134466
3.

Selective Inhibitors of Nuclear Export (SINE) compounds block proliferation and migration of triple negative breast cancer cells by restoring expression of ARRDC3.

Soung YH, Kashyap T, Nguyen T, Yadav G, Chang H, Landesman Y, Chung J.

Oncotarget. 2017 May 18;8(32):52935-52947. doi: 10.18632/oncotarget.17987. eCollection 2017 Aug 8.

4.

Selinexor-induced thrombocytopenia results from inhibition of thrombopoietin signaling in early megakaryopoiesis.

Machlus KR, Wu SK, Vijey P, Soussou TS, Liu ZJ, Shacham E, Unger TJ, Kashyap T, Klebanov B, Sola-Visner M, Crochiere M, Italiano JE Jr, Landesman Y.

Blood. 2017 Aug 31;130(9):1132-1143. doi: 10.1182/blood-2016-11-752840. Epub 2017 Jun 19.

PMID:
28630120
5.

A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia.

Garzon R, Savona M, Baz R, Andreeff M, Gabrail N, Gutierrez M, Savoie L, Mau-Sorensen PM, Wagner-Johnston N, Yee K, Unger TJ, Saint-Martin JR, Carlson R, Rashal T, Kashyap T, Klebanov B, Shacham S, Kauffman M, Stone R.

Blood. 2017 Jun 15;129(24):3165-3174. doi: 10.1182/blood-2016-11-750158. Epub 2017 Mar 23.

6.

The elevated activation of NFκB and AP-1 is correlated with differential regulation of Bcl-2 and associated with oral squamous cell carcinoma progression and resistance.

Alam M, Kashyap T, Pramanik KK, Singh AK, Nagini S, Mishra R.

Clin Oral Investig. 2017 Dec;21(9):2721-2731. doi: 10.1007/s00784-017-2074-6. Epub 2017 Feb 23.

PMID:
28233171
7.

The Exportin-1 Inhibitor Selinexor Exerts Superior Antitumor Activity when Combined with T-Cell Checkpoint Inhibitors.

Farren MR, Hennessey RC, Shakya R, Elnaggar O, Young G, Kendra K, Landesman Y, Elloul S, Crochiere M, Klebanov B, Kashyap T, Burd CE, Lesinski GB.

Mol Cancer Ther. 2017 Mar;16(3):417-427. doi: 10.1158/1535-7163.MCT-16-0498. Epub 2017 Feb 1.

8.

Clinical Dosing Regimen of Selinexor Maintains Normal Immune Homeostasis and T-cell Effector Function in Mice: Implications for Combination with Immunotherapy.

Tyler PM, Servos MM, de Vries RC, Klebanov B, Kashyap T, Sacham S, Landesman Y, Dougan M, Dougan SK.

Mol Cancer Ther. 2017 Mar;16(3):428-439. doi: 10.1158/1535-7163.MCT-16-0496. Epub 2017 Feb 1.

9.

XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.

Turner JG, Kashyap T, Dawson JL, Gomez J, Bauer AA, Grant S, Dai Y, Shain KH, Meads M, Landesman Y, Sullivan DM.

Oncotarget. 2016 Nov 29;7(48):78896-78909. doi: 10.18632/oncotarget.12969.

10.

Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-κB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death.

Kashyap T, Argueta C, Aboukameel A, Unger TJ, Klebanov B, Mohammad RM, Muqbil I, Azmi AS, Drolen C, Senapedis W, Lee M, Kauffman M, Shacham S, Landesman Y.

Oncotarget. 2016 Nov 29;7(48):78883-78895. doi: 10.18632/oncotarget.12428.

11.

Reversion-inducing cysteine-rich protein with Kazal motifs and its regulation by glycogen synthase kinase 3 signaling in oral cancer.

Pramanik KK, Singh AK, Alam M, Kashyap T, Mishra P, Panda AK, Dey RK, Rana A, Nagini S, Mishra R.

Tumour Biol. 2016 Nov;37(11):15253-15264. Epub 2016 Sep 30.

PMID:
27696293
12.

XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase IIα to the Nucleus.

Ranganathan P, Kashyap T, Yu X, Meng X, Lai TH, McNeil B, Bhatnagar B, Shacham S, Kauffman M, Dorrance AM, Blum W, Sampath D, Landesman Y, Garzon R.

Clin Cancer Res. 2016 Dec 15;22(24):6142-6152. Epub 2016 Jun 29.

13.

Preparing to read the ubiquitin code: characterization of ubiquitin trimers by top-down mass spectrometry.

Lee AE, Geis-Asteggiante L, Dixon EK, Kim Y, Kashyap TR, Wang Y, Fushman D, Fenselau C.

J Mass Spectrom. 2016 Apr;51(4):315-21. doi: 10.1002/jms.3759.

14.

Deciphering mechanisms of drug sensitivity and resistance to Selective Inhibitor of Nuclear Export (SINE) compounds.

Crochiere M, Kashyap T, Kalid O, Shechter S, Klebanov B, Senapedis W, Saint-Martin JR, Landesman Y.

BMC Cancer. 2015 Nov 17;15:910. doi: 10.1186/s12885-015-1790-z.

15.

Prevalence of Bovine Aortic Arch Configuration in Adult Patients with and without Thoracic Aortic Pathology.

Moorehead PA, Kim AH, Miller CP, Kashyap TV, Kendrick DE, Kashyap VS.

Ann Vasc Surg. 2016 Jan;30:132-7. doi: 10.1016/j.avsg.2015.05.008. Epub 2015 Jul 10.

PMID:
26166538
16.

Selective Nuclear Export Inhibitor KPT-330 Enhances the Antitumor Activity of Gemcitabine in Human Pancreatic Cancer.

Kazim S, Malafa MP, Coppola D, Husain K, Zibadi S, Kashyap T, Crochiere M, Landesman Y, Rashal T, Sullivan DM, Mahipal A.

Mol Cancer Ther. 2015 Jul;14(7):1570-81. doi: 10.1158/1535-7163.MCT-15-0104. Epub 2015 May 1.

17.

Novel small molecule XPO1/CRM1 inhibitors induce nuclear accumulation of TP53, phosphorylated MAPK and apoptosis in human melanoma cells.

Yang J, Bill MA, Young GS, La Perle K, Landesman Y, Shacham S, Kauffman M, Senapedis W, Kashyap T, Saint-Martin JR, Kendra K, Lesinski GB.

PLoS One. 2014 Jul 24;9(7):e102983. doi: 10.1371/journal.pone.0102983. eCollection 2014.

18.

Biologic activity of the novel orally bioavailable selective inhibitor of nuclear export (SINE) KPT-335 against canine melanoma cell lines.

Breit MN, Kisseberth WC, Bear MD, Landesman Y, Kashyap T, McCauley D, Kauffman MG, Shacham S, London CA.

BMC Vet Res. 2014 Jul 15;10:160. doi: 10.1186/1746-6148-10-160.

19.

Unique structural, dynamical, and functional properties of k11-linked polyubiquitin chains.

Castañeda CA, Kashyap TR, Nakasone MA, Krueger S, Fushman D.

Structure. 2013 Jul 2;21(7):1168-81. doi: 10.1016/j.str.2013.04.029.

20.

CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications.

Tai YT, Landesman Y, Acharya C, Calle Y, Zhong MY, Cea M, Tannenbaum D, Cagnetta A, Reagan M, Munshi AA, Senapedis W, Saint-Martin JR, Kashyap T, Shacham S, Kauffman M, Gu Y, Wu L, Ghobrial I, Zhan F, Kung AL, Schey SA, Richardson P, Munshi NC, Anderson KC.

Leukemia. 2014 Jan;28(1):155-65. doi: 10.1038/leu.2013.115. Epub 2013 Apr 16.

21.

Nonenzymatic assembly of branched polyubiquitin chains for structural and biochemical studies.

Dixon EK, Castañeda CA, Kashyap TR, Wang Y, Fushman D.

Bioorg Med Chem. 2013 Jun 15;21(12):3421-9. doi: 10.1016/j.bmc.2013.02.052. Epub 2013 Mar 15.

22.
23.

Role of β4 integrin phosphorylation in human invasive squamous cell carcinoma: regulation of hemidesmosome stability modulates cell migration.

Kashyap T, Germain E, Roche M, Lyle S, Rabinovitz I.

Lab Invest. 2011 Oct;91(10):1414-26. doi: 10.1038/labinvest.2011.104. Epub 2011 Jul 18.

24.

Controlled enzymatic synthesis of natural-linkage, defined-length polyubiquitin chains using lysines with removable protecting groups.

Castañeda CA, Liu J, Kashyap TR, Singh RK, Fushman D, Cropp TA.

Chem Commun (Camb). 2011 Feb 21;47(7):2026-8. doi: 10.1039/c0cc04868b. Epub 2011 Jan 6.

25.

Use of repeated matings to estimate environmental and genetic trends and effects of relaxing selection in a selected strain of Leghorn chickens.

Dickerson GE, Kashyap TS, Bennett GL, Goodwin K, Emsley JA.

Poult Sci. 1983 Feb;62(2):212-26.

PMID:
6835898

Supplemental Content

Loading ...
Support Center